Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

Area of Science:

• Immunology and Cancer Therapy
• Tumor Microenvironment Modulation

Background:

• Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating tumor-specific immune responses.
• Current DC therapy, involving ex vivo loading with tumor-associated antigens (TAAs), has limited clinical efficacy in many patients.
• The immunosuppressive tumor microenvironment (TME) and tumor characteristics significantly impede DC therapy effectiveness.

Purpose of the Study:

• To review and evaluate clinical strategies for combining dendritic cell (DC) therapy with other treatments.
• To explore how combining DC therapy with conventional therapies can overcome the immunosuppressive TME.
• To improve the overall efficacy of DC-based cancer immunotherapies.

Main Methods:

• Review of existing clinical data and research on combination therapies involving dendritic cell (DC) therapy.
• Analysis of how conventional treatments (chemotherapy, radiotherapy) and immunotherapies (checkpoint inhibitors) impact the TME.
• Evaluation of strategies that combine DC therapy with registered cancer treatments.

Main Results:

• Conventional cancer therapies can augment anti-tumor immunity by targeting immunosuppressive cells in the TME.
• These therapies can induce immunogenic cell death (ICD) and block inhibitory molecules, potentially synergizing with DC therapy.
• Combining DC therapy with chemotherapy, radiotherapy, or checkpoint inhibitors presents a promising strategy to enhance immune responses.

Conclusions:

• Combining dendritic cell (DC) therapy with established treatments like chemotherapy, radiotherapy, or checkpoint inhibitors is a viable strategy.
• Such combination approaches hold the potential to overcome the immunosuppressive tumor microenvironment (TME) and improve clinical outcomes.
• Further evaluation of these clinical combination strategies is warranted to optimize DC therapy efficacy.